Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia

Neil P. Shah, Hagop M. Kantarjian, Dong Wook Kim, Delphine Réa, Pedro E. Dorlhiac-Llacer, Jorge H. Milone, Jorge Vela-Ojeda, Richard T. Silver, H. Jean Khoury, Aude Charbonnier, Nina Khoroshko, Ronald L. Paquette, Michael Deininger, Robert H. Collins, Irma Otero, Timothy Hughes, Eric Bleickardt, Lewis Strauss, Stephen Francis, Andreas Hochhaus

Research output: Contribution to journalArticlepeer-review

408 Scopus citations

Fingerprint

Dive into the research topics of 'Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia'. Together they form a unique fingerprint.

Medicine & Life Sciences